Friday, 25 September 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 31, 2025

Best Wegovy Alternative for 2026? FDA Approves Oral Semaglutide as Patients Evaluate Compounded Telehealth Access — Direct Meds Examined as Verification Case Study

View original at globenewswire.com
Best Wegovy Alternative for 2026? FDA Approves Oral Semaglutide as Patients Evaluate Compounded Telehealth Access — Direct Meds Examined as Verification Case Study Bluffdale, UT, Dec…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Exercising more topped Americans' New Year's resolutions for 2026, with 25% of respondents listing it as their primary goal

    80% confidence
  • Approximately 48% of respondents ranked fitness goals as their highest priority heading into the new year

    80% confidence
  • Compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved medication

    80% confidence
  • The agency is not aware of a basis for compounding using semaglutide sodium or semaglutide acetate salt forms

    80% confidence
  • Oral semaglutide 25 mg represents a significant advancement in obesity treatment

    80% confidence
  • Approximately 12.4% of U.S. adults now report taking GLP-1 drugs for weight loss, more than double the 5.8% measured in February 2024

    80% confidence
  • About half of adults who have taken GLP-1 drugs reported difficulty affording the cost

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Scale Up Through Partnerships and Funding, But Data Readiness Lags Ambition
A wave of vertical AI-agent startups (Swarm, Veridox, Avallon AI, DA2, F2, Earthian, Meanwhile, Covecta, Penguin AI, Maisa AI) is being funded and profiled just as major infrastructure players — Microsoft/Mistral, Siemens/NVIDIA, and Manulife/Microsoft — cement enterprise AI governance and compute partnerships. Yet a Google Cloud report shows AI agents still lack access to the majority of company data (only 45% on average), and insider selling at incumbent C3.ai signals investor caution even as adoption intent (100% planned agentic AI use within two years) races ahead of actual data infrastructure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com